MARKET

OPT

OPT

Opthea Ltd
NASDAQ
3.410
0.000
0.00%
Suspension 10:04 03/17 EDT
OPEN
3.410
PREV CLOSE
3.410
HIGH
3.410
LOW
3.410
VOLUME
0
TURNOVER
--
52 WEEK HIGH
6.30
52 WEEK LOW
1.790
MARKET CAP
524.84M
P/E (TTM)
-1.4013
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OPT last week (0428-0502)?
Weekly Report · 5d ago
Weekly Report: what happened at OPT last week (0421-0425)?
Weekly Report · 04/28 09:24
Weekly Report: what happened at OPT last week (0414-0418)?
Weekly Report · 04/21 09:24
Weekly Report: what happened at OPT last week (0407-0411)?
Weekly Report · 04/14 09:22
Weekly Report: what happened at OPT last week (0331-0404)?
Weekly Report · 04/07 09:22
Opthea Limited (CKDXF) was downgraded to a Sell Rating at Bell Potter
TipRanks · 04/02 13:55
Opthea terminates COAST trial, announces ShORe trial misses endpoint
TipRanks · 03/31 09:45
Weekly Report: what happened at OPT last week (0324-0328)?
Weekly Report · 03/31 09:24
More
About OPT
More
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Recently
Symbol
Price
%Change

Webull offers Opthea Ltd (ADR) stock information, including NASDAQ: OPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OPT stock methods without spending real money on the virtual paper trading platform.